Cancer

Success Beyond Startup: Nurturing Growth as a Co-Founder with Kilo Health

VILNIUS, LITHUANIA / ACCESSWIRE / December 20, 2023 / From developing healthcare systems to personalized fitness apps such as Joggo,…

1 year ago

MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials

VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer…

1 year ago

BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset

In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of…

1 year ago

Poolbeg Pharma PLC Announces RSV AI Drug Candidate Analysis Update

Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AIRSV drug candidates with the highest probability of success…

1 year ago

23-Provider Dermatology Clinic Increases Patient Engagement and Clinic Growth With eClinicalWorks EHR and healow Patient Engagement Solutions

healow Open Access enables digital access for the growing patient population and reduces no-shows at Skin Solutions DermatologyWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®,…

1 year ago

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by…

1 year ago

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) CARDIFF, United Kingdom, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX),…

1 year ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical…

1 year ago

Kimia Therapeutics Raises $55 Million Series A

– Fundraise led by The Column Group and Dimension – – Kimia is advancing its ATLAS platform that combines high-throughput…

1 year ago